A Guide to Selecting Flexible Survival Models to Inform Economic Evaluations of Cancer Immunotherapies
Open Access
- 13 August 2022
- journal article
- research article
- Published by Elsevier BV in Value in Health
- Vol. 26 (2), 185-192
- https://doi.org/10.1016/j.jval.2022.07.009
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb
- National Institute for Health and Care Research
This publication has 36 references indexed in Scilit:
- Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipatedBMC Medical Research Methodology, 2016
- Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trialThe Lancet, 2015
- Adjusting for measurement error in baseline prognostic biomarkers included in a time-to-event analysis: a joint modelling approachBMC Medical Research Methodology, 2013
- Cognitive-behavioural interventions for children who have been sexually abusedEmergencias, 2012
- The Ends Justify the Mean: Outcome Measures for Estimating the Value of New Cancer TherapiesHealth Outcomes Research in Medicine, 2012
- Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival modelsBMC Medical Research Methodology, 2011
- Accounting for Uncertainty in Health Economic Decision Models by Using Model AveragingJournal of the Royal Statistical Society Series A: Statistics in Society, 2009
- Bayesian evidence synthesis to extrapolate survival estimates in cost-effectiveness studiesStatistics in Medicine, 2005
- Survival plots of time-to-event outcomes in clinical trials: good practice and pitfallsThe Lancet, 2002
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994